Free Trial

Valneva (VALN) Competitors

Valneva logo
$5.88 -0.19 (-3.13%)
As of 06/17/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VALN vs. SRPT, RXRX, APGE, IDYA, INDV, CGON, BLTE, GLPG, HRMY, and IRON

Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Sarepta Therapeutics (SRPT), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), IDEAYA Biosciences (IDYA), Indivior (INDV), CG Oncology (CGON), Belite Bio (BLTE), Galapagos (GLPG), Harmony Biosciences (HRMY), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

Valneva vs. Its Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Sarepta Therapeutics received 1446 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 74.74% of users gave Sarepta Therapeutics an outperform vote while only 66.67% of users gave Valneva an outperform vote.

CompanyUnderperformOutperform
Sarepta TherapeuticsOutperform Votes
1488
74.74%
Underperform Votes
503
25.26%
ValnevaOutperform Votes
42
66.67%
Underperform Votes
21
33.33%

Sarepta Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Sarepta Therapeutics has a net margin of -11.12% compared to Valneva's net margin of -43.08%. Sarepta Therapeutics' return on equity of -14.88% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-11.12% -14.88% -5.12%
Valneva -43.08%-43.05%-16.23%

Sarepta Therapeutics currently has a consensus target price of $74.13, indicating a potential upside of 243.83%. Valneva has a consensus target price of $15.50, indicating a potential upside of 163.61%. Given Sarepta Therapeutics' higher possible upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
1 Sell rating(s)
10 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.54
Valneva
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sarepta Therapeutics has higher revenue and earnings than Valneva. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$1.90B1.11$235.24M-$2.69-8.01
Valneva$183.52M2.73-$13.25M-$1.19-4.94

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 83 more articles in the media than Valneva. MarketBeat recorded 87 mentions for Sarepta Therapeutics and 4 mentions for Valneva. Valneva's average media sentiment score of 0.70 beat Sarepta Therapeutics' score of -0.35 indicating that Valneva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
7 Very Positive mention(s)
15 Positive mention(s)
23 Neutral mention(s)
21 Negative mention(s)
6 Very Negative mention(s)
Neutral
Valneva
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Sarepta Therapeutics beats Valneva on 12 of the 19 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VALN vs. The Competition

MetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$510.26M$10.12B$5.33B$8.57B
Dividend YieldN/A2.08%5.32%4.20%
P/E Ratio-4.9418.0925.9419.01
Price / Sales2.7328.95424.50111.98
Price / Cash61.3722.6335.6355.74
Price / Book2.443.607.825.05
Net Income-$13.25M$232.68M$3.15B$249.31M
7 Day Performance-4.87%-3.46%-2.62%-1.87%
1 Month Performance-6.89%-1.64%4.42%2.24%
1 Year Performance-17.18%-15.22%35.79%15.05%

Valneva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VALN
Valneva
2.5109 of 5 stars
$5.88
-3.1%
$15.50
+163.6%
-17.0%$510.26M$183.52M-4.94700Gap Down
SRPT
Sarepta Therapeutics
4.5668 of 5 stars
$20.94
-42.1%
$99.35
+374.4%
-81.5%$2.06B$2.23B16.75840Trending News
Analyst Forecast
Options Volume
High Trading Volume
RXRX
Recursion Pharmaceuticals
1.9094 of 5 stars
$5.00
+1.6%
$7.00
+40.0%
-48.3%$2.03B$59.82M-3.27400Analyst Forecast
APGE
Apogee Therapeutics
2.4271 of 5 stars
$42.61
-4.2%
$94.60
+122.0%
+6.8%$1.96BN/A-17.6191Positive News
IDYA
IDEAYA Biosciences
3.7793 of 5 stars
$22.39
+0.9%
$54.27
+142.4%
-41.6%$1.96B$7M-6.7880
INDV
Indivior
2.7307 of 5 stars
$14.18
+2.1%
$15.00
+5.8%
-15.7%$1.96B$1.17B-40.511,164Positive News
CGON
CG Oncology
2.4732 of 5 stars
$25.46
-1.5%
$58.22
+128.7%
-22.2%$1.94B$662K-16.8661Positive News
Analyst Forecast
BLTE
Belite Bio
2.6529 of 5 stars
$59.99
+0.7%
$96.67
+61.1%
+18.0%$1.91BN/A-54.0410Short Interest ↑
GLPG
Galapagos
0.2173 of 5 stars
$28.80
+0.1%
$25.33
-12.0%
+8.5%$1.90B$288.19M0.001,310
HRMY
Harmony Biosciences
4.7827 of 5 stars
$32.90
-0.2%
$53.00
+61.1%
+10.6%$1.89B$744.85M15.59200Positive News
Short Interest ↑
IRON
Disc Medicine
2.204 of 5 stars
$52.02
-3.1%
$96.70
+85.9%
+11.6%$1.80BN/A-13.0730Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:VALN) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners